Logo

Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis

Share this

Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis

Shots: Shots:

  • The P-III ADVANCE study involves assessing of Otezla (apremilast- 30mg- bid for 16wks.) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis. Later- patients will receive Otezla during an open-label extension phase @32wks.
  • The P-III ADVANCE study results: @16wks.- improvement in its 1EPs of sPGA score; achieve 2EPs i.e- 75% improvement in BSA- change in PASI score  
  • Otezla is a selective PDE4 inhibitor- inhibiting the production of TNF-alpha from human rheumatoid synovial cells and is an approved therapy for mod. to sev. plaque psoriasis who are candidates for phototherapy or systemic therapy- for active PsA and for with oral ulcers associated with Behçet's Disease

Click here ­to­ read full press release/ article | Ref: Amgen | Image: StraitTimes

Related News: Amgen Receives Health Canada’s Marketing Authorization Transfer of Otezla for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions